Value of the HLA-B*5701 allele to predict abacavir hypersensitivity in Spaniards

AIDS Research and Human Retroviruses

Volumn 23, Issue 11, 2007, Pages 1374-1376

  Rodríguez Nóvoa, Sonia ^a   García Gascó, Pilar ^a   Blanco, Francisco ^a   González Pardo, Gema ^a   Castellares, Carol ^a   Moreno, Victoria ^a   Jiménez Nácher, Inmaculada ^a   González Lahoz, Juan ^a   Soriano, Vincent ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; EFAVIRENZ; HLA B57 ANTIGEN; HLA B5701 ANTIGEN; NEVIRAPINE; UNCLASSIFIED DRUG; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; HLA B ANTIGEN; HLA B*5701 ANTIGEN, HUMAN; HLA-B*5701 ANTIGEN, HUMAN;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERSENSITIVITY REACTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SPAIN; DRUG HYPERSENSITIVITY; GENETIC SCREENING; GENETICS; PREDICTION AND FORECASTING;

ANTI-HIV AGENTS; DIDEOXYNUCLEOSIDES; DRUG HYPERSENSITIVITY; GENETIC SCREENING; HLA-B ANTIGENS; HUMANS; PREDICTIVE VALUE OF TESTS; SPAIN;

EID: 38449112126     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2006.0244     Document Type: Article

References (11)

1. Mallal S, Nolan D, Witt C, et al.: Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse transcriptase inhibitor abacavir. Lancet 2002;359:727-732.
2. Hetherington S, Hughes A, Mosteller M, et al.: Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 2002;359:1121-1122.
3. Nolan D, Gaudieri S, and Mallal S: Pharmacogenetics: A practical role in predicting antiretroviral drug toxicity? J HIV Ther 2003;8:36-41.
4. Cao K, Hollenbach J, Shi X, Shi W, Chopek M, and Fernandez-Vina MA: Analysis of the frequencies of HLA-A, B, and C alleles and haplotypes in the five major ethnic groups of the United States reveals high levels of diversity in these loci and contrasting distribution patterns in these populations. Hum Immunol 2001;62:1009-1030.
5. Symonds W, Cutrell A, Edwards M, et al.: Risk factor analysis of hypersensitivity reactions to abacavir. Clin Ther 2002;24:565-573.
6. Campillo J, Martinez-Escribano J, Muro M, et al.: HLA class I and class II frequencies in patients with cutaneous malignant melanoma from southeastern Spain: the role of HLA-C in disease prognosis. Immunogenetics 2006;57:926-933.
7. Phillips E, Rauch A, Nolan D, et al.: Pharmacogenetics and clinical characterictics of patch test confirmed patients with abacavir hypersensitivity. In: 7th International Workshop on Clinical Pharmacology of HIV Therapy. 20-22 April 2006, Lisbon, Portugal [abstract 33].
8. Martin A, Nolan D, Gaudieri S, et al.: Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proc Natl Acad Sci USA 2004;101:4180-4185.
9. Hughes A, Mosteller M, Bansal A, et al.: Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. Pharmacogenomics 2004;5:203-211.
10. Rauch A, Nolan D, Martin A, McKinnon E, Almeida C, and Mallal S: Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study. Clin Infect Dis 2006;43:99-102.
11. Hughes D, Vilar F, Ward C, Alfirevic A, Park B, and Pirmohamed M: Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity. Pharmacogenetics 2004;14:335-342.